Parallel Artificial Membrane Permeability Assay

In early drug discovery and lead compound optimization, membrane permeability is a pivotal physicochemical and biopharmaceutical parameter that directly predicts a compound's ability to cross biological barriers, particularly gastrointestinal (GI) mucosal membranes, which determines oral absorption potential and overall bioavailability. The Parallel Artificial Membrane Permeability Assay (PAMPA) has emerged as the gold-standard, high-throughput in vitro permeability screening method, offering a simplified, cell-free alternative to cell-based assays (e.g., Caco-2) for passive transcellular permeability assessment.

PharmaAnalytica delivers a robust, standardized Parallel Artificial Membrane Permeability Assay (PAMPA) Service, custom-designed for rapid, high-throughput permeability screening of lead compounds. This non-cell, cost-effective assay accurately measures passive diffusion across an artificial lipid membrane, mimicking the intestinal epithelial barrier, to generate reliable permeability coefficients (Pe) and rank compound absorption potential. Fully optimized for limited-quantity novel leads, PAMPA accelerates lead prioritization, supports Biopharmaceutics Classification System (BCS) categorization, and enables data-driven decisions to eliminate poorly permeable candidates early in development.

Applications in Lead Studies

• High-Throughput Lead Permeability Screening: Rapidly rank large libraries of lead compounds based on passive permeability, prioritizing highly permeable candidates for further optimization and eliminating poorly absorbed molecules early.
• BCS Classification Support: Combine permeability data with equilibrium solubility results to categorize drug candidates into BCS classes (I-IV), guiding formulation and regulatory strategies.
• pH-Dependent Permeability Testing: Evaluate permeability across physiological pH ranges (pH 5.0–7.4) to assess pH-sensitive absorption and predict GI tract absorption variability.
• Lead Analog SAR Analysis: Compare permeability across structural analogs to guide molecular modification, optimizing passive diffusion and oral absorption potential.
• Alternative to Cell-Based Assays: Serve as a fast, cost-effective preliminary screening tool before Caco-2 or MDCK cell assays, reducing resource consumption and accelerating timelines.
• Formulation Feasibility Assessment: Evaluate the impact of solubilizers, excipients, and pH modifiers on compound permeability to support early preformulation design.

PharmaAnalytica's Technology Platform

PharmaAnalytica's PAMPA Service

High-Throughput Custom Screening Service

We deliver efficient parallel testing for large lead compound libraries via our standardized 96-well platform, supporting rapid batch screening and shortening lead optimization cycles significantly, far more efficient than in-house cell-based assay workflows.

Strict Quality & Compliance Control

Our PAMPA testing follows full GLP-aligned SOPs, with regular instrument calibration and system suitability verification. We eliminate assay variability through strict environmental and operational control, ensuring all data is traceable, repeatable and defensible for regulatory review.

Flexible Customized Testing Protocols

We offer tailored pH conditions, incubation times and media formulations based on your lead compound properties and project goals, adapting to unique screening requirements for diverse small-molecule candidates.

Regulatory-Ready Expert Deliverables

Our professional scientific team compiles comprehensive, ICH-aligned test reports with complete methodology, raw data and expert interpretation, directly supporting early drug development documentation, candidate progression and IND-enabling studies.

Membrane permeability is a non-negotiable parameter for predicting oral drug absorption and reducing late-stage development attrition. PharmaAnalytica's Parallel Artificial Membrane Permeability Assay (PAMPA) service combines high-throughput automation, reliable instrumentation, and lead-focused scientific expertise to deliver fast, accurate permeability data, streamlining lead prioritization, optimizing formulation strategies, and accelerating the advancement of high-quality drug candidates toward clinical development.